1. Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy 
Thomas J. Smith, MD, Patrick J. Coyne, RN, MSN, Gwendolyn L. Parker, RN, MSN, Patricia Dodson, BSN, MA, Viswanathan Ramakrishnan, PhD 
Journal of Pain and Symptom Management 
Volume 40, Issue 6, Pages (December 2010)
DOI: /j.jpainsymman
Copyright © Terms and Conditions

2. Fig. 1
The MC5-A Calmare® device positioned to treat stocking-glove neuropathy.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions

3. Fig. 2
Effect of MC5-A Calmare® therapy on pain scores during treatment. P< by paired t-test, two-tailed.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions

4. Fig. 3
Effect of MC5-A Calmare® therapy on pain scores. Overall reduction in pain score is 64%; P<0.001 by repeated-measures analysis of variance.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions

5. Fig. 4
Duration of effect of MC5-A Calmare® therapy on pain scores: pain relief over time.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions